Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV+ Patients

Epstein-Barr virus (EBV) is an oncogenic virus associated with the development of aggressive and poor-prognosis B-cell lymphomas in patients infected with human immunodeficiency virus (HIV patients). The most important risk factors for these malignancies include immune dysfunction, chronic immune ac...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 9; p. 2291
Main Authors Hernández, Diana M., Valderrama, Sandra, Gualtero, Sandra, Hernández, Catalina, López, Marcos, Herrera, Maria Victoria, Solano, Julio, Fiorentino, Susana, Quijano, Sandra
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 04.10.2018
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2018.02291

Cover

More Information
Summary:Epstein-Barr virus (EBV) is an oncogenic virus associated with the development of aggressive and poor-prognosis B-cell lymphomas in patients infected with human immunodeficiency virus (HIV patients). The most important risk factors for these malignancies include immune dysfunction, chronic immune activation, and loss of T-cell receptor (TCR) repertoire. The combination of all these factors can favor the reactivation of EBV, malignant cell transformation, and clinical progression toward B-cell lymphomas. The overarching aim of this study was to evaluate the frequency, phenotype, functionality, and distribution of TCR clonotypes for EBV-specific T-cell subpopulations in HIV patients at different clinical stages and for HIV patients with B-cell lymphoma, as well as to establish their association with clinical variables of prognostic value. Factors were studied in 56 HIV patients at different clinical stages and in six HIV+ subjects with diagnosed B-cell lymphoma. We found a significant decrease in all subpopulations of EBV-specific CD4 T cells from HIV patients at stage 3 and with B-cell lymphoma. EBV-specific effector CD8 T cells, particularly effector memory cells, were also reduced in HIV patients with B-cell lymphoma. Interestingly, these cells were unable to produce IFN-γ and lacked multifunctionality in HIV+ patients. The TCR-Vβ repertoire, which is key for protection against EBV in healthy individuals, was less diverse in HIV patients due to a lower frequency of TCR-Vβ2 , Vβ4 , Vβ7.1 , Vβ9 , Vβ13.6 , Vβ14 , Vβ17 , Vβ22 CD4 , Vβ14 , and Vβ17 CD8 T cells. HIV patients with positive plasma EBV loads (EBV HIV ) had a noteworthy decrease in the levels of both TNF-α and multifunctional TNF-α /IL-2 and TNF-α /IFN-γ CD8 T cells. Altogether, our findings demonstrate that HIV patients have significant alterations in the immune response to EBV (poor-quality immunity) that can favor viral reactivation, escalating the risk for developing EBV-associated B-cell lymphomas.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Aurelio Cafaro, Istituto Superiore di Sanità (ISS), Italy
This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Reviewed by: Vijayakumar Velu, Emory University, United States; Riccardo Gavioli, University of Ferrara, Italy
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2018.02291